Class IITerminated

Bevacizumab 1.75 mg/0.07 mL recall

FDA recall D-0003-2026 · initiated Sep 22, 2025

May cause temporary or medically reversible harm; low probability of serious harm.

Why it was recalled

Lack of assurance of sterility.

Details

Product: Bevacizumab 1.75 mg/0.07 mL - 0.25 mL syringe, Intravitreal, 0.07 mL Total Volume, Rx Only, Hospital/Office Use Only, Refrigerate, RC Outsourcing LLC, Lowellville, OH 44436.
Recalling company: RC Outsourcing, LLC
Classification: Class II
Status: Terminated
Type: Voluntary: Firm initiated
Distribution: Nationwide in the US
Initiated: Sep 22, 2025
FDA report date: Oct 15, 2025

What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.

Source: openFDA Drug Enforcement record D-0003-2026 ↗

← All drug recalls